<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485184</url>
  </required_header>
  <id_info>
    <org_study_id>PVT-TIPS2</org_study_id>
    <nct_id>NCT02485184</nct_id>
  </id_info>
  <brief_title>TIPS vs Endoscopic Therapy for Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis</brief_title>
  <official_title>TIPS Versus Endoscopic Therapy for the Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Provincial Hospital Affiliated to Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Affiliated Hospital of Sun Yat-sen Universityg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital Affiliated to Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      portal vein thrombosis may be a negative prognostic marker of variceal bleeding in liver
      cirrhosis. Compared with conventional endoscopic and pharmacological therapy, transjugular
      intrahepatic portosystemic shunt may further improve the outcomes of portal vein thrombosis
      in liver cirrhosis with variceal bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Portal vein thrombosis may be a negative prognostic marker of variceal bleeding in liver
      cirrhosis. Compared with conventional endoscopic and pharmacological therapy, transjugular
      intrahepatic portosystemic shunt may further improve the outcomes of portal vein thrombosis
      in liver cirrhosis with variceal bleeding. However, the safety of transjugular intrahepatic
      portosystemic shunt remains uncertain in patients with portal vein thrombosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause rebleeding or all-cause death</measure>
    <time_frame>3 years</time_frame>
    <description>Cumulative incidence of all-cause rebleeding or all-cause death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Portal vein recanalization</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence of portal vein recanalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other decompensations of portal hypertension</measure>
    <time_frame>3 years</time_frame>
    <description>defined as ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events of treatment</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence of adverse events of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>quality of life assessed by the SF-36 health survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatocellular Carcinoma</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence of Hepatocellular Carcinoma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Portal Vein Thrombosis</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>TIPS group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transjugular intrahepatic portosystemic shunt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ET &amp; drugs groups</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endoscopic therapy.
Non-selective beta blockers.
Anticoagulation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transjugular intrahepatic portosystemic shunt</intervention_name>
    <description>Transjugular intrahepatic portosystemic shunt refers to an interventional radiological procedure by placing a stent between portal vein and hepatic vein. No specific device was used in the Interventional field.</description>
    <arm_group_label>TIPS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-selective beta blockers</intervention_name>
    <description>Non-selective beta blockers are the drugs for reducing the portal pressure.</description>
    <arm_group_label>ET &amp; drugs groups</arm_group_label>
    <other_name>propranolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic therapy</intervention_name>
    <description>Endoscopic therapy includes the endoscopic variceal band ligation</description>
    <arm_group_label>ET &amp; drugs groups</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anticoagulation</intervention_name>
    <description>Anticoagulation therapy includes heparin and warfarin.</description>
    <arm_group_label>ET &amp; drugs groups</arm_group_label>
    <other_name>warfarin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. liver cirrhosis (histological or clinical);

          2. Significant variceal bleeding &gt;5 days and â‰¤ 42 days

          3. Successful treatment of the index bleed by means of vasoactive drugs and/or endoscopic
             treatment

          4. Portal vein thrombosis occlusion&gt;=25% of the vessel lumen;

          5. Presence of ascites

          6. Child-Pugh score 8-12 at inclusion

          7. Age 18 to 70 years

        Exclusion criteria

          1. Bleeding from isolated gastric or ectopic varices

          2. Contraindications to non-selective beta blockers (chronic obstructive pulmonary
             disease, asthma, aortic stenosis, atrioventricular block, intermittent claudication,
             and psychosis)

          3. Contraindications to TIPS : extensive potral vein thrombosis, fibrotic cord replacing
             original main portal vein; bilirubin&gt;3.5 mg/dL, plasma creatinine&gt;2.1 mg/dL,
             Child-Pugh score &gt;=13points

          4. A history of significant heart failure (New York Heart Association class III and IV)

          5. Overt hepatic encephalopathy,

          6. Prehepatic portal hypertension

          7. Malignancy (including hepatocellular carcinoma) or a concomitant disease with reduced
             life expectancy

          8. Uncontrolled infection and sepsis

          9. Previous treatment to prevent rebleeding with a portosystemic shunt,TIPS or with
             pharmacological therapy with non-selective beta blockers and endoscopic variceal
             ligation

         10. Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guohong Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital of Digestive Diseases, Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guohong Han, MD</last_name>
    <email>hangh@fmmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yong Lv, MD</last_name>
    <email>lvyong126@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xijing Hospital of digestive disease, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guohong Han, MD,Ph.D</last_name>
      <email>hangh@fmmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Guohong Han, MD,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yong Lv, MD,Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital Affiliated to Southern Medical Univers</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianbo Zhao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ming-an Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Provincial Hospital Affiliated to Shandong University</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chunqing Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xuan Zhu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuzheng Zhuge, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumchi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weixin Ren, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Han G, Qi X, He C, Yin Z, Wang J, Xia J, Yang Z, Bai M, Meng X, Niu J, Wu K, Fan D. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol. 2011 Jan;54(1):78-88. doi: 10.1016/j.jhep.2010.06.029. Epub 2010 Aug 27.</citation>
    <PMID>20932597</PMID>
  </reference>
  <reference>
    <citation>Lv Y, He C, Wang Z, Guo W, Wang J, Bai W, Zhang L, Wang Q, Liu H, Luo B, Niu J, Li K, Tie J, Yin Z, Fan D, Han G. Association of Nonmalignant Portal Vein Thrombosis and Outcomes after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis. Radiology. 2017 Dec;285(3):999-1010. doi: 10.1148/radiol.2017162266. Epub 2017 Jul 5.</citation>
    <PMID>28682164</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Guohong Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

